AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...

Owing to the low incidence of AL amyloidosis, large studies are scarce and hardly any randomized, controlled studies comparing different therapeutic regimens have been conducted. Comparison of studies ...

“AL amyloidosis is a fatal disease and systemic therapy is required to prevent deposition of amyloid in other organs and prevent progressive organ failure.” “In this manuscript, we discuss the general ...

ORLANDO, Fla. - Cardiac amyloidosis is a systemic disorder that affects the heart and can also affect other organs such as the kidneys and nervous system. AdventHealth says approximately 50-150,000 ...

Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup Primary systemic ...

Alnylam stock popped Thursday on a solid first-quarter beat for its Pfizer-rivaling heart disease drug, Amvuttra.

Please provide your email address to receive an email when new articles are posted on . “Teclistamab has already been approved in multiple myeloma, and there is institutional data where it shows that ...

Primary (AL) amyloidosis is the most prevalent type of systemic amyloidosis, and management of this disease has evolved through the years from supportive care to aggressive treatments that include ...